Recent Finacing
Recent Raise
Peroxitech develops inhaled peptide PIP-2 that targets Prdx6/NOX2 oxidative signaling to prevent and treat acute lung injury; demonstrated preclinical protection and is advancing IND‑enabling studies toward clinical development.
